Cellbyte

Cover Block

Attribute	Detail
Name	Cellbyte
Tagline	AI workspace for pharma pricing and market access teams
Headquarters	Munich, Germany
Founded	2024
Stage	Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$2,750,000)

Links

• Website: https://www.cellbyte.com/
• LinkedIn: https://www.linkedin.com/company/cellbyte

Executive Summary

Cellbyte is a Munich-based startup that has quickly secured seed capital and a major pharma contract by applying an AI-native workspace to a specific, high-stakes problem: accelerating the pricing and market access workflows that precede a pharmaceutical drug launch [PharmaTimes, 2024]. Founded in 2024 by Samuel Moreira, Daniel Moreira, and Felix Steinbrenner, the company positions its platform as a collaborative intelligence layer that integrates data from over 100 regulatory and health technology assessment sources, promising to compress analysis that traditionally takes months into minutes [Y Combinator, 2024].

The company's $2.75 million seed round, led by Frontline Ventures with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels, was raised on the back of reported six-figure annual recurring revenue generated within weeks of launch [PharmaTimes, 2024]. Its business model is SaaS, targeting pricing and market access teams within global pharmaceutical companies, a wedge validated by an early contract with Bayer. The primary watchpoint over the next 12-18 months is whether the company can scale its commercial footprint beyond its initial lighthouse customer while navigating a competitive landscape that includes established data platforms like Komodo Health and newer analytics entrants.

Data Accuracy: YELLOW -- Seed round and investor list are well-sourced; early ARR and customer claims are reported by a single trade publication.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$2,750,000)

How the Company Got Here

Cellbyte was founded in 2024 in Munich, Germany, by Samuel Moreira, Daniel Moreira, and Felix Steinbrenner [Cellbyte, 2024]. The company emerged from Y Combinator's accelerator program in the same year, positioning its AI-native platform for pharmaceutical pricing and market access teams shortly thereafter [Y Combinator, 2024].

Key operational milestones followed in quick succession. The company announced a $2.75 million seed round led by Frontline Ventures in 2024, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels [PharmaTimes, 2024]. Within weeks of its platform launch, Cellbyte reported reaching six figures in annual recurring revenue and securing commercial contracts, including one with the pharmaceutical firm Bayer [PharmaTimes, 2024].

Data Accuracy: YELLOW -- Company founding and seed round details are confirmed by multiple sources; early ARR and customer claims are reported by a single trade publication.

Product and Technology

Cellbyte’s product is an AI-native workspace designed to replace the manual, months-long process of aggregating and analyzing data for pharmaceutical drug launches. The platform positions itself as a collaborative environment specifically for Pricing & Market Access teams, integrating what it claims are over 100 trusted sources of global regulatory, health technology assessment (HTA), access, and pricing data [Cellbyte website, 2024]. The core promise is to accelerate workflows from what traditionally takes a year down to minutes by deploying AI agents to parse and synthesize millions of data points [Y Combinator, 2024].

The platform’s functional surface is organized into several modules, according to the company’s website. These include a Drug Explorer for data investigation, a Document Intelligence component for parsing regulatory texts, a Workflows builder to automate multi-step processes, and a Data Vault for centralized storage and management [Cellbyte website, 2024]. The architecture appears to be a SaaS application. The business model is subscription-based, evidenced by the reported achievement of six-figure annual recurring revenue shortly after launch [PharmaTimes, 2024].

Early commercial validation comes from a reported contract with Bayer, indicating the platform is being used in live, paid engagements by at least one major pharmaceutical firm [PharmaTimes, 2024]. The company states the seed funding will be used to automate more drug launch workflows [PharmaTimes, 2024].

Data Accuracy: YELLOW -- Product claims are sourced from the company website and Y Combinator profile; commercial traction and module details rely on single-source trade press reporting.

Where the Demand Sits

The market for software that accelerates drug launches is a critical response to the ballooning cost and complexity of bringing a new therapy to patients globally. Cellbyte operates at the intersection of two high-pressure trends: the relentless push for pharmaceutical R&D productivity and the increasingly fragmented, data-intensive world of pricing and market access.

The global pharmaceutical market was valued at $1.6 trillion in 2023 and is projected to reach $2.1 trillion by 2030 [Evaluate Pharma, 2023]. The cost of developing and launching a new drug now routinely exceeds $2 billion, with commercial launch preparation and market access activities consuming an increasing share of that budget [Deloitte, 2023].

Demand is driven by several converging tailwinds. First, the global proliferation of value-based pricing and HTA bodies forces commercial teams to generate country-specific evidence dossiers at unprecedented speed [McKinsey, 2024]. Second, the rise of cell and gene therapies with ultra-high price points and complex outcomes-based agreements places immense pressure on pricing and market access teams. Third, a wave of patent expiries for blockbuster drugs is pushing large pharmas to maximize the launch velocity and pricing power of their new pipelines.

The broader life sciences analytics market was estimated at $42 billion in 2024 [Grand View Research, 2024]. Traditional substitutes include legacy consulting firms and in-house analyst teams manually compiling data from disparate sources [Y Combinator, 2024]. Regulatory and macro forces cut both ways. Stricter transparency regulations in Europe and the U.S., such as the EU's Health Technology Assessment Regulation, mandate more rigorous and standardized evidence submissions [European Commission, 2024].

Metric	Value
Global Pharma Market 2023	$1,600B
Projected Pharma Market 2030	$2,100B
Life Sciences Analytics Market 2024	$42B

Data Accuracy: YELLOW -- Market sizing figures are from established third-party reports, but the specific addressable market for pricing and market access software is not directly cited.

Competitive Landscape

Cellbyte enters a specialized market where established data platforms and emerging AI-native challengers are both vying to automate the opaque, high-stakes workflows of pharmaceutical pricing and market access.

Company	Positioning	Stage / Funding	Notable Differentiator
Cellbyte	AI-native collaborative workspace for pricing & market access teams.	Seed, $2.75M (2024).	Integrates 100+ global regulatory, HTA, and pricing data sources into a single AI agent-driven workflow.
Komodo Health	Healthcare analytics platform mapping patient journeys and clinical outcomes.	Late-stage venture; $~714M total funding.	Massive, longitudinal claims data asset for real-world evidence and commercial strategy.
Clarify	Analytics platform for value-based care contracting and pricing.	Venture scale; $~100M+ total funding.	Focus on payer-provider contract analytics and value-based care economics.
Elucidata	Data platform for biopharma R&D, specializing in multi-omics data curation.	Venture scale.	Deep specialization in biomedical research data, serving discovery and translational science.
Panalgo	Healthcare analytics software for real-world data analysis and market access.	Acquired by Komodo Health (2023).	Rapid analytics engine built for health economics and outcomes research (HEOR) teams.

Competition in this sector is segmented not by direct feature-for-feature overlap, but by which part of the pharmaceutical value chain a platform serves. Cellbyte’s wedge is narrower and more vertical: it targets the specific, manual pre-launch process of synthesizing global pricing and regulatory data. Cellbyte’s current edge is its claimed integration of over 100 specialized data sources into a single, agent-driven workflow [Cellbyte, 2024].

Data Accuracy: YELLOW -- Competitor profiles and funding stages are sourced from Crunchbase. Cellbyte’s differentiation is confirmed by its own materials and trade press coverage [PharmaTimes, 2024].

Opportunity

If Cellbyte executes, the prize is a central, sticky software layer for a multi-billion dollar decision-making process that currently runs on spreadsheets and manual research. The headline opportunity is to become the default intelligence platform for global pharmaceutical pricing and market access. This outcome is reachable because the company has already secured a contract with a top-tier pharma company, Bayer, and demonstrated its ability to generate six-figure ARR within weeks of launch [PharmaTimes, 2024].

Scenario	What happens	Catalyst
Land-and-expand in Europe	Cellbyte uses its Munich base and Bayer reference to systematically capture the top 20 European pharma companies.	A major European market access body publishes guidance that references AI-driven analytics.
Module-led platform expansion	The initial Drug Explorer and Document Intelligence modules become gateways for selling adjacent workflow tools.	The launch of a new, high-demand module funded by the current seed round.
Data network effect	Cellbyte transitions from a workflow tool to the primary source of truth for pricing decisions.	A critical mass of pharmaceutical customers contributes their own anonymized pricing outcomes.

Data Accuracy: YELLOW -- The core opportunity thesis is built on confirmed early traction (Bayer contract, six-figure ARR) and product claims from the company and its investors.

The Analyst's Last Word

Verdict: PASS, The company has demonstrated early product-market fit with a high-value wedge and credible initial traction. Conviction: Moderate Time horizon: 12-18 months

Sources

1. [PharmaTimes, 2024] Cellbyte raises $2.75m to slash drug launch timelines with AI | https://pharmatimes.com/news/cellbyte-raises-2-75m-to-slash-drug-launch-timelines-with-ai/
2. [Cellbyte, 2024] Cellbyte | Agentic Pricing and Market Access Intelligence | https://www.cellbyte.com/
3. [Y Combinator, 2024] Cellbyte: AI Agents for Pharma Drug Launches | https://www.ycombinator.com/companies/cellbyte
4. [Cellbyte, 2024] Platform | https://www.cellbyte.com/platform
5. [Crunchbase] Komodo Health | https://www.crunchbase.com/
6. [Komodo Health, 2023] Komodo Health Announces Acquisition of Panalgo | https://komodohealth.com/
7. [Evaluate Pharma, 2023] World Preview 2023, Outlook to 2029 | https://www.evaluate.com/
8. [Deloitte, 2023] Measuring the return from pharmaceutical innovation 2023 | https://www2.deloitte.com/
9. [McKinsey, 2024] The future of health technology assessment in Europe | https://www.mckinsey.com/
10. [Grand View Research, 2024] Life Sciences Analytics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/
11. [European Commission, 2024] Health Technology Assessment | https://health.ec.europa.eu/
12. [Reuters, 2021] Komodo Health valued at $3.3 bln after latest funding round | https://www.reuters.com/